Source: Eur Respir Rev 2010 19: 279-287
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Vachiéry J-L., Simonneau G.. Management of severe pulmonary arterial hypertension. Eur Respir Rev 2010 19: 279-287

Member's Comments

No comment yet.

Related content which might interest you: The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 589-596 Year: 2012 Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management Source: Eur Respir Rev 2010 19: 314-320 Year: 2010 Effect of sildenafil on exercise ability of patients with World Health Organization functional class II pulmonary arterial hypertension Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals Source: Eur Respir Rev 2010 19: 272-278 Year: 2010 Pulmonary hypertension: diagnosis, differential diagnosis and pitfalls Source: Eur Respir Mon 2012; 57: 17-25 Year: 2012 Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation Source: Eur Respir J 2010; 35: 1079-1087 Year: 2010 Global fibrinolytic profile in patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 Age is independently associated with pulmonary arterial compliance in health and in patients with pulmonary vascular disease Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Baseline hemodynamic predictors of treatment response in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Effects of pulmonary rehabilitation (PR) in idiopathic pulmonary arterial hypertension (PAHI) Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2) Year: 2013 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Update on current treatment options of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management Source: Eur Respir J, 53 (1) 1801916; 10.1183/13993003.01916-2018 Year: 2019 Social deprivation and prognosis in Scottish patients with pulmonary arterial hypertension Source: Eur Respir J, 51 (2) 1700444; 10.1183/13993003.00444-2017 Year: 2018 Survival in pulmonary hypertension in Spain: insights from the Spanish registry}, Source: Eur Respir J 2012; 40: 596-603 Year: 2012 Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Issues related to the management and therapy of paediatric pulmonary hypertension Source: Eur Respir Rev 2010 19: 331-339 Year: 2010